scholarly journals Relativistic corrections to bound-state energies for two-fermion systems

1984 ◽  
Vol 30 (10) ◽  
pp. 2189-2193 ◽  
Author(s):  
F. Gesztesy ◽  
H. Grosse ◽  
B. Thaller

2009 ◽  
Vol 42 (14) ◽  
pp. 145001 ◽  
Author(s):  
M Dineykhan ◽  
S A Zhaugasheva ◽  
N Sh Toinbaeva ◽  
A Jakhanshir


2011 ◽  
Vol 89 (1) ◽  
pp. 117-122 ◽  
Author(s):  
Michael I. Eides ◽  
Timothy J.S. Martin

We discuss the leading relativistic (nonrecoil and recoil) corrections to bound state g-factors of particles with arbitrary spin. These corrections are universal for any spin and depend only on the free particle gyromagnetic ratios. We explain the physical reasons behind this universality.







2017 ◽  
Vol 32 (35) ◽  
pp. 1747003
Author(s):  
A. Hasenfratz ◽  
R. C. Brower ◽  
C. Rebbi ◽  
E. Weinberg ◽  
O. Witzel

The dynamical origin of electroweak symmetry breaking is an open question with many possible theoretical explanations. Strongly coupled systems predicting the Higgs boson as a bound state of a new gauge-fermion interaction form one class of candidate models. Due to increased statistics, LHC run II will further constrain the phenomenologically viable models in the near future. In the meanwhile it is important to understand the general properties and specific features of the different competing models. In this work we discuss many-flavor gauge-fermion systems that contain both massless (light) and massive fermions. The former provide Goldstone bosons and trigger electroweak symmetry breaking, while the latter indirectly influence the infrared dynamics. Numerical results reveal that such systems can exhibit a light [Formula: see text] isosinglet scalar, well separated from the rest of the spectrum. Further, when we set the scale via the vev of electroweak symmetry breaking, we predict a 2 TeV vector resonance which could be a generic feature of SU(3) gauge theories.



2007 ◽  
Vol 85 (8) ◽  
pp. 813-836 ◽  
Author(s):  
A G Terekidi ◽  
J W Darewych ◽  
M Horbatsch

We present a formulation of the Hamiltonian variational method for quantum electrodynamics (QED) that enables the derivation of a relativistic few-fermion wave equation that can account, at least in principle, for interactions to any order of the coupling constant. We derive a relativistic two-fermion wave equation using this approach. The interaction kernel of the equation is shown to be the generalized invariant [Formula: see text] matrix including all orders of Feynman diagrams. The result is obtained rigorously from the underlying quantum field theory (QFT) for an arbitrary mass ratio of the two fermions. Our approach is based on three key points: a reformulation of QED, the variational method, and adiabatic hypothesis. As an application, we calculate the one-loop contribution of radiative corrections to the two-fermion binding energy for singlet states with arbitrary principal quantum number n, and [Formula: see text] = J = 0. Our calculations are carried out in the explicitly covariant Feynman gauge.PACS Nos.: 12.20.–m



Author(s):  
John Trinickt ◽  
Howard White

The primary force of muscle contraction is thought to involve a change in the myosin head whilst attached to actin, the energy coming from ATP hydrolysis. This change in attached state could either be a conformational change in the head or an alteration in the binding angle made with actin. A considerable amount is known about one bound state, the so-called strongly attached state, which occurs in the presence of ADP or in the absence of nucleotide. In this state, which probably corresponds to the last attached state of the force-producing cycle, the angle between the long axis myosin head and the actin filament is roughly 45°. Details of other attached states before and during power production have been difficult to obtain because, even at very high protein concentration, the complex is almost completely dissociated by ATP. Electron micrographs of the complex in the presence of ATP have therefore been obtained only after chemically cross-linking myosin subfragment-1 (S1) to actin filaments to prevent dissociation. But it is unclear then whether the variability in attachment angle observed is due merely to the cross-link acting as a hinge.We have recently found low ionic-strength conditions under which, without resorting to cross-linking, a high fraction of S1 is bound to actin during steady state ATP hydrolysis. The structure of this complex is being studied by cryo-electron microscopy of hydrated specimens. Most advantages of frozen specimens over ambient temperature methods such as negative staining have already been documented. These include improved preservation and fixation rates and the ability to observe protein directly rather than a surrounding stain envelope. In the present experiments, hydrated specimens have the additional benefit that it is feasible to use protein concentrations roughly two orders of magnitude higher than in conventional specimens, thereby reducing dissociation of weakly bound complexes.





Author(s):  
Parth Sarthi Sen Gupta ◽  
Satyaranjan Biswal ◽  
Saroj Kumar Panda ◽  
Abhik Kumar Ray ◽  
Malay Kumar Rana

<p>While an FDA approved drug Ivermectin was reported to dramatically reduce the cell line of SARS-CoV-2 by ~5000 folds within 48 hours, the precise mechanism of action and the COVID-19 molecular target involved in interaction with this in-vitro effective drug are unknown yet. Among 12 different COVID-19 targets studied here, the RNA dependent RNA polymerase (RdRp) with RNA and Helicase NCB site show the strongest affinity to Ivermectin amounting -10.4 kcal/mol and -9.6 kcal/mol, respectively. Molecular dynamics of corresponding protein-drug complexes reveals that the drug bound state of RdRp with RNA has better structural stability than the Helicase NCB site, with MM/PBSA free energy of -135.2 kJ/mol, almost twice that of Helicase (-76.6 kJ/mol). The selectivity of Ivermectin to RdRp is triggered by a cooperative interaction of RNA-RdRp by ternary complex formation. Identification of the target and its interaction profile with Ivermectin can lead to more powerful drug designs for COVID-19 and experimental exploration. </p>



Sign in / Sign up

Export Citation Format

Share Document